5,6-Dihydroxypyrimidine-4-carboxylic acids are a promising series of hepatitis C virus (HCV) NS5B polymerase inhibitors that bind at the active site of the enzyme. Here we report a simple 2-thienyl substituted analogue that shows 10-fold improved activity over the original lead, and which allowed us to further delineate the key elements of the pharmacophore of this class of inhibitor. This work led to the identification of a trifluoromethyl acylsulfonamide group as a viable replacement for the C4 carboxylic acid in this series. (C) 2004 Elsevier Ltd. All rights reserved.
HIV-1 NUCLEOCAPSID INHIBITORS
申请人:Università degli Studi di Siena
公开号:EP3290412A1
公开(公告)日:2018-03-07
The present invention discloses novel anti-HIV agents targeting the HIV Nucleocapsid protein (NC), which is one of the most conserved sequences within HIV strains and is highly required for HIV replication. The compounds of the invention are particularly useful to overcome antiretroviral drug-resistance in HIV-1 infected individuals.